NCT02934412View on ClinicalTrials.gov

A Study of SHR-1314 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 22, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Psoriasis
Interventions
DRUG

SHR-1314

Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

DRUG

placebo

Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

Trial Locations (1)

2000

Atridia Pty Limited, Sydney

All Listed Sponsors
lead

Atridia Pty Ltd.

INDUSTRY

NCT02934412 - A Study of SHR-1314 in Healthy Subjects | Biotech Hunter | Biotech Hunter